Related Experiment Videos
Effects of calcium channel blockers on survival after myocardial infarction
1National Heart, Lung and Blood Institute, Bethesda, Maryland 20892.
Cardiovascular Drugs and Therapy
|December 1, 1987
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.
The Journal of clinical endocrinology and metabolism·2012
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.
Journal of thrombosis and haemostasis : JTH·2011
The influence of experimental hyperthyroidism on responsiveness in rabbit aortic smooth muscle.
Environmental toxicology and pharmacology·2011
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.
European journal of preventive cardiology·2011
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Diabetic medicine : a journal of the British Diabetic Association·2010
Allopurinol for Marfan Aortopathy: Pharmacogenomic Safety and Sex-Stratified Trial Design Warrant Consideration.
Cardiovascular drugs and therapy·2026
METTL3 Confers Ischemia/Reperfusion-Caused Myocardial Injury by Triggering Ferroptosis via Regulating the lncRNA SNHG14/miR-195a-5p/ACSL4 Axis.
Cardiovascular drugs and therapy·2026
PDK4-Associated Metabolic Reprogramming Contributes to Lactate Accumulation and Parthanatos-Related Changes in Septic Cardiomyocytes.
Cardiovascular drugs and therapy·2026
Herpes Zoster Vaccination as Cardiovascular Prevention in Adults with Heart Disease.
Cardiovascular drugs and therapy·2026
Impact of Diabetes on Coronary Plaque Stabilization With Evolocumab: Insights From the YELLOW III Trial.
Cardiovascular drugs and therapy·2026